PLoS ONE (Jan 2022)

Reduced midbrain raphe echogenicity in patients with fibromyalgia syndrome.

  • Nurcan Üçeyler,
  • Mira Schließer,
  • Dimitar Evdokimov,
  • Jakub Radziwon,
  • Betty Feulner,
  • Stefan Unterecker,
  • Florian Rimmele,
  • Uwe Walter

DOI
https://doi.org/10.1371/journal.pone.0277316
Journal volume & issue
Vol. 17, no. 11
p. e0277316

Abstract

Read online

ObjectivesThe pathogenesis of fibromyalgia syndrome (FMS) is unclear. Transcranial ultrasonography revealed anechoic alteration of midbrain raphe in depression and anxiety disorders, suggesting affection of the central serotonergic system. Here, we assessed midbrain raphe echogenicity in FMS.MethodsSixty-six patients underwent transcranial sonography, of whom 53 were patients with FMS (27 women, 26 men), 13 patients with major depression and physical pain (all women), and 14 healthy controls (11 women, 3 men). Raphe echogenicity was graded visually as normal or hypoechogenic, and quantified by digitized image analysis, each by investigators blinded to the clinical diagnosis.ResultsQuantitative midbrain raphe echogenicity was lower in patients with FMS compared to healthy controls (pConclusionWe found reduced echogenicity of the midbrain raphe area in patients with FMS and in patients with depression and physical pain, independent of the presence or severity of pain, FMS, and depressive symptoms. Further exploration of this sonographic finding is necessary before this objective technique may enter diagnostic algorithms in FMS and depression.